摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-溴-2,4-二甲氧基吡啶 | 52606-07-2

中文名称
5-溴-2,4-二甲氧基吡啶
中文别名
——
英文名称
5-bromo-2,4-dimethoxypyridine
英文别名
——
5-溴-2,4-二甲氧基吡啶化学式
CAS
52606-07-2
化学式
C7H8BrNO2
mdl
——
分子量
218.05
InChiKey
IRLDCGSNDXFFQH-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    245.1±35.0 °C(Predicted)
  • 密度:
    1.484±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.8
  • 重原子数:
    11
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.29
  • 拓扑面积:
    31.4
  • 氢给体数:
    0
  • 氢受体数:
    3

安全信息

  • 危险性防范说明:
    P261,P264,P270,P271,P280,P301+P312,P302+P352,P304+P340,P305+P351+P338,P330,P332+P313,P337+P313,P362,P403+P233,P405,P501
  • 危险性描述:
    H302,H315,H319,H335

SDS

SDS:cab6bafeacfcd0727d3dbc59a4a87fe5
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • New bicyclic compounds as crac channel modulators
    申请人:Almirall, S.A.
    公开号:EP2738172A1
    公开(公告)日:2014-06-04
    The present invention relates to novel compounds which are inhibitors of CRAC channel activity. This invention also relates to pharmaceutical compositions containing them, process for their preparation and their use in therapy.
    这项发明涉及一种新型化合物,它们是CRAC通道活性的抑制剂。该发明还涉及含有这些化合物的药物组合物,它们的制备方法以及它们在治疗中的应用。
  • [EN] NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS<br/>[FR] NOUVEAUX DERIVES DE PYRIDINONE ET LEUR UTILISATION EN TANT QUE MODULATEURS ALLOSTERIQUES POSITIFS DES RECEPTEURS MGLUR2
    申请人:JANSSEN PHARMACEUTICA NV
    公开号:WO2006030032A1
    公开(公告)日:2006-03-23
    The present invention relates to novel compounds, in particular novel pyridinone derivat ives according to Formula (I) X R1 N Y (I) R2 R3 wherein all radicals are defined in the application. The compounds according to the invention are positive allosteric modulators of metabotropic receptors - subt ype 2 ('mGluR2') which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.
    本发明涉及新化合物,特别是根据式(I)X R1 N Y(I)R2 R3定义的新吡啶酮衍生物。根据本发明的化合物是代谢型受体-亚型2('mGluR2')的阳性变构调节剂,对于治疗或预防与谷氨酸功能障碍相关的神经和精神障碍以及涉及代谢型受体的mGluR2亚型的疾病具有用处。特别是,这些疾病是从焦虑、精神分裂症、偏头痛、抑郁症和癫痫等中枢神经系统障碍组中选择的。该发明还涉及制备此类化合物和组合物的药物组合物和过程,以及利用这类化合物预防和治疗涉及mGluR2的这类疾病。
  • ANTI-FIBROTIC PYRIDINONES
    申请人:InterMune, Inc.
    公开号:US20140094456A1
    公开(公告)日:2014-04-03
    Disclosed are pyridinone compounds, method for preparing these compounds, and methods for treating fibrotic disorders.
    揭示了吡啶酮化合物,制备这些化合物的方法,以及治疗纤维化疾病的方法。
  • SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF
    申请人:Blackburn Christopher
    公开号:US20110212969A1
    公开(公告)日:2011-09-01
    This invention provides compounds of formula (I): wherein ring A, X 1 , X 2 , X 3 , R 2 , R 4b , R 10 , and G have values as described in the specification, useful as inhibitors of HDAC6. The invention also provides pharmaceutical compositions comprising the compounds of the invention, and methods of using the compositions in the treatment of proliferative, inflammatory, infectious, neurological or cardiovascular diseases or disorders.
    这项发明提供了式(I)的化合物: 其中环A、X1、X2、X3、R2、R4b、R10和G的取值如规范中所述,可用作HDAC6的抑制剂。该发明还提供了包括该发明化合物的药物组合物,以及在治疗增殖性、炎症性、感染性、神经系统或心血管疾病或紊乱中使用该组合物的方法。
  • PYRIDINYL-SUBSTITUTED PYRAZOLYL CARBOXAMIDES
    申请人:GRÜNENTHAL GMBH
    公开号:US20150166505A1
    公开(公告)日:2015-06-18
    The invention relates to pyrazolyl-based carboxamide compounds useful as ICRAC inhibitors, to pharmaceutical compositions containing these compounds and to methods of using these compounds for the treatment and/or prophylaxis of diseases and/or disorders, in particular inflammatory diseases and/or inflammatory disorders.
    这项发明涉及以吡唑基为基础的羧酰胺化合物,其作为ICRAC抑制剂有用,涉及含有这些化合物的药物组合物以及使用这些化合物治疗和/或预防疾病和/或疾病的方法,特别是炎症性疾病和/或炎症性疾病。
查看更多